Health ❯ Healthcare ❯ Oncology ❯ Lung Cancer

Non-Small Cell Lung Cancer

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

The company plans an NDA to seek approval of the subcutaneous version across toripalimab’s existing indications.

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

High-Dose Steroids Undermine Checkpoint Inhibitors in Non-Small Cell Lung Cancer